[go: up one dir, main page]

RU2006132127A - APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR - Google Patents

APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR Download PDF

Info

Publication number
RU2006132127A
RU2006132127A RU2006132127/15A RU2006132127A RU2006132127A RU 2006132127 A RU2006132127 A RU 2006132127A RU 2006132127/15 A RU2006132127/15 A RU 2006132127/15A RU 2006132127 A RU2006132127 A RU 2006132127A RU 2006132127 A RU2006132127 A RU 2006132127A
Authority
RU
Russia
Prior art keywords
component
nifuroxazide
drug therapy
pylori
helicobacter pylori
Prior art date
Application number
RU2006132127/15A
Other languages
Russian (ru)
Inventor
Петр Леонидович Щербаков (RU)
Петр Леонидович Щербаков
Александр Сергеевич Потапов (RU)
Александр Сергеевич Потапов
Елена Сергеевна Дублина (RU)
Елена Сергеевна Дублина
Марина Юрьевна Щербакова (RU)
Марина Юрьевна Щербакова
Галина Андреевна Самсыгина (RU)
Галина Андреевна Самсыгина
Светлана Ильинична Эрдес (RU)
Светлана Ильинична Эрдес
Анна Игоревна Логвинова (RU)
Анна Игоревна Логвинова
вцева Лариса Васильевна Кудр (RU)
Лариса Васильевна Кудрявцева
Original Assignee
Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru)
Государственное Учреждение Научный Центр Здоровья Детей Российской Академии Медицинских Наук (Гу Нцзд Рамн)
Государственное Образовательное Учреждение Высшего Профессионального Образования "Российский Государственный Медицинский Университет" Росздрава (Гоу Впо "Ргму" Росздрава) (Ru)
Государственное Образовательное Учреждение Высшего Профессионального Образования "Российский Государственный Медицинский Университет" Росздрава (Гоу Впо "Ргму" Росздрава)
Босналиек, Фармасьютикал Энд Камикал Индастри, Джойнт Сток Компани (Ba)
Босналиек, Фармасьютикал Энд Камикал Индастри, Джойнт Сток Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru), Государственное Учреждение Научный Центр Здоровья Детей Российской Академии Медицинских Наук (Гу Нцзд Рамн), Государственное Образовательное Учреждение Высшего Профессионального Образования "Российский Государственный Медицинский Университет" Росздрава (Гоу Впо "Ргму" Росздрава) (Ru), Государственное Образовательное Учреждение Высшего Профессионального Образования "Российский Государственный Медицинский Университет" Росздрава (Гоу Впо "Ргму" Росздрава), Босналиек, Фармасьютикал Энд Камикал Индастри, Джойнт Сток Компани (Ba), Босналиек, Фармасьютикал Энд Камикал Индастри, Джойнт Сток Компани filed Critical Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru)
Priority to RU2006132127/15A priority Critical patent/RU2006132127A/en
Priority to PCT/RU2007/000477 priority patent/WO2008030141A1/en
Priority to RSP-2009/0150A priority patent/RS20090150A/en
Publication of RU2006132127A publication Critical patent/RU2006132127A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (11)

1. Применение нифуроксазида в качестве компонента комбинированной лекарственной терапии заболевания желудочно-кишечного тракта, ассоциированного с инфекцией Helicobacter pylori, где комбинированная лекарственная терапия направлена на эрадикацию возбудителя и включает нифуроксазид, компонент, регулирующий процессы кислотообразования в желудке, выбранный из ингибитора протонной помпы или блокатора Н2-рецепторов гистамина, по меньшей мере один дополнительный антибактериальный компонент, эффективный против Н.pylori, и/или висмута трикалия дицитрат.1. The use of nifuroxazide as a component of combination drug therapy for a disease of the gastrointestinal tract associated with Helicobacter pylori infection, where the combination drug therapy is aimed at eradicating the pathogen and includes nifuroxazide, a component that regulates acid formation in the stomach, selected from a proton pump inhibitor or blocker H 2 histamine receptors, at least one additional component is an antibacterial effective against H. pylori and / or bismuth tripotassium ditsit al. 2. Применение по п.1, в котором ингибитором протонной помпы является омепразол.2. The use according to claim 1, in which the proton pump inhibitor is omeprazole. 3. Применение по п.1, в котором по меньшей мере один дополнительный антибактериальный компонент, эффективный против Н. pylori, выбирают из амоксициллина, кларитромицина, или тетрациклина.3. The use according to claim 1, in which at least one additional antibacterial component effective against H. pylori is selected from amoxicillin, clarithromycin, or tetracycline. 4. Применение по п.1, где лекарственная терапия представляет собой эрадикацию возбудителя.4. The use according to claim 1, where the drug therapy is the eradication of the pathogen. 5. Способ лечения заболевания желудочно-кишечного тракта, ассоциированного с инфекцией Helicobacter pylori, предусматривающий комбинированную лекарственную терапию, включающую введение субъекту, нуждающемуся в этом, нифуроксазида, компонента, регулирующего процессы кислотообразования в желудке, выбранного из ингибитора протонной помпы или блокатора Н2-рецепторов гистамина, и по меньшей мере одного дополнительного антибактериального компонента, эффективного против Н.pylori, и/или висмута трикалия дицитрат.5. A method of treating a disease of the gastrointestinal tract associated with Helicobacter pylori infection, comprising combination drug therapy, comprising administering to a subject in need thereof nifuroxazide, a component that regulates acid formation in the stomach, selected from a proton pump inhibitor or an H 2 receptor blocker histamine, and at least one additional antibacterial component effective against H. pylori and / or bismuth tripotassium dicitrate. 6. Способ по п.5, в котором ингибитором протонной помпы является омепразол.6. The method according to claim 5, in which the proton pump inhibitor is omeprazole. 7. Способ по п.5, в котором по меньшей мере один дополнительный антибактериальный компонент, эффективный против Н. pylori, выбирают из амоксициллина, кларитромицина, и тетрациклина.7. The method according to claim 5, in which at least one additional antibacterial component effective against H. pylori is selected from amoxicillin, clarithromycin, and tetracycline. 8. Способ по п.5, в котором нифуроксазид используют в лекарственной форме, представляющей собой суспензию для орального применения.8. The method according to claim 5, in which nifuroxazide is used in a dosage form, which is a suspension for oral administration. 9. Способ по п.5, в котором в качестве препарата, действующим веществом которого является нифуроксазид, используют Энтерофурил.9. The method according to claim 5, in which Enterofuril is used as a preparation, the active substance of which is nifuroxazide. 10. Способ по п.9, в котором препарат Энтерофурил используют в виде суспензии для орального применения.10. The method according to claim 9, in which Enterofuril is used as a suspension for oral use. 11. Способ по п.5, в котором субъектом, нуждающимся в лекарственной терапии, является ребенок.11. The method according to claim 5, in which the subject in need of drug therapy is a child.
RU2006132127/15A 2006-09-06 2006-09-06 APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR RU2006132127A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU2006132127/15A RU2006132127A (en) 2006-09-06 2006-09-06 APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR
PCT/RU2007/000477 WO2008030141A1 (en) 2006-09-06 2007-09-05 Use of nifuroxazide in the form of a component of a combined drug therapy for treating diseases associated with helicobacter pylori and a curing method for eradicating a causative agent
RSP-2009/0150A RS20090150A (en) 2006-09-06 2007-09-05 Use of nifuroxazide in the form of a component of a combined drug therapy for treating diseases associated with helicobacter pylori and a curing method for eradicating a causative agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2006132127/15A RU2006132127A (en) 2006-09-06 2006-09-06 APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR

Publications (1)

Publication Number Publication Date
RU2006132127A true RU2006132127A (en) 2008-03-20

Family

ID=39157480

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006132127/15A RU2006132127A (en) 2006-09-06 2006-09-06 APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR

Country Status (3)

Country Link
RS (1) RS20090150A (en)
RU (1) RU2006132127A (en)
WO (1) WO2008030141A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446797C1 (en) * 2011-02-24 2012-04-10 Петр Леонидович Щербаков Method of treating acid-dependent conditions associated with helicobacter pylori

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313519B1 (en) * 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201930D0 (en) * 1992-06-24 1992-06-24 Astra Ab GASTRIC ANTIBACTERIAL TREATMENT
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9700885D0 (en) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446797C1 (en) * 2011-02-24 2012-04-10 Петр Леонидович Щербаков Method of treating acid-dependent conditions associated with helicobacter pylori

Also Published As

Publication number Publication date
RS20090150A (en) 2010-10-31
WO2008030141A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
JP2016164165A5 (en)
EA200870325A1 (en) MEDICAL FORMS FOR THE INTRODUCTION OF COMBINATIONS OF MEDICINES
RU2007132181A (en) ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR
JP2006501240A5 (en)
WO2009017716A3 (en) Pulsatile gastric retentive dosage forms
RU2001107149A (en) TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS
JP2020108787A (en) Intraluminal treatment system for gastrointestinal infections
JP2013541583A (en) Combination composition
JP2008500288A (en) Oral therapeutic compound delivery system
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
CN109893516A (en) For treating the pharmaceutical composition of helicobacter pylori
EP4309722A3 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2002525266A5 (en)
EA022204B1 (en) Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
WO2006134492A3 (en) Acarbose methods and formulations for treating chronic constipation
RU2004131214A (en) METHODS FOR TREATING COGNITIVE DISORDERS
RU2002127800A (en) APPLICATION OF CD25-BINDING MOLECULES FOR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT
RU2006132127A (en) APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR
AU2016277587B2 (en) Buffered upper GI absorption promoter
RU2006139819A (en) APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION
US11813286B2 (en) Composition and therapy for treatment of gag reflexes
RU2016144695A (en) COMPLEX OF SITAGLIPTIN TANNA
RU2253449C1 (en) Method for eradication of infection heliobacter pylory in stomach
JP2011178722A (en) PHARMACEUTICAL COMPOSITION TO ELIMINATE HELICOBACTER PYLORI (H.pylori) AND METHOD FOR PRODUCING THE SAME
RU2004134082A (en) ANTI-GRIPPOINT MEANS

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20091211